national stem-cell therapy logo

Stem Cell Therapy for Peripheral Arterial Disease Relief

Stem Cell Therapy for Peripheral Arterial Disease

At the intersection of innovation and healthcare, stem cell therapy offers new hope for individuals with peripheral arterial disease (PAD). PAD affects a significant number of people worldwide, primarily in the lower extremity arteries, causing symptoms such as limb pain, ulcers, and necrosis. Circulation is crucial for the treatment of PAD, but traditional options like […]

Harnessing Mesenchymal Stem Cells for Cardiac Regeneration: A Leap Towards Mending Broken Hearts

Human heart surrounded by stem cells

Heart ailments are among the leading causes of mortality and morbidity worldwide. The spectrum of heart disease encompasses conditions like myocardial infarction (heart attack), ischemic heart disease, heart failure, and numerous others. While modern medicine has made significant strides in managing these conditions, the ability to fundamentally restore the damaged cardiac tissue remains largely unattained. […]

BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies

BioCardia Logo

SUNNYVALE, Calif., April 04, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the issuance of two patent grants related to enabling technologies for delivery of its investigational autologous and allogeneic cell therapies. The United States Patent Office issued BioCardia Patent […]

Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting

BioCardia Logo

SUNNYVALE, Calif., March 06, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces that detailed echocardiography data from the roll-in cohort of the Phase III CardiAMP® Cell Therapy Heart Failure Trial is being presented today at the American College of Cardiology annual meeting by […]

Is Stem Cell Therapy Right for You? Evaluating Your Candidacy

Middle age man considering stem cell therapy

Stem cell therapy is an exciting area of medical research and treatment that has the potential to revolutionize the way we approach many health conditions. Stem cells have unique properties that allow them to renew themselves and differentiate into many different types of cells in the body. This makes them a promising tool for repairing […]

BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial Two-Year Data at HFSA Annual Meeting

BioCardia Logo

SUNNYVALE, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces data from its FDA designated Breakthrough CardiAMP® Cell Therapy for Heart Failure pivotal trial (ClinicalTrials.gov Identifier: NCT02438306) presented at the Heart Failure Society of America meeting in Washington, […]

How Stem Cells Contribute to Aging and Age-Related Diseases with Rob Signer

Ages tennis player teaching tennis

What challenges does aging pose to both individuals and society at large? What causes aging at the cellular and molecular level? Stem cell research is the key to finding solutions that increase our healthspan and change how we think about aging. Robert A.J. Signer, Ph.D., shares what is on the horizon. Video Transcript: [MUSIC] What […]

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

BioCardia Logo

SUNNYVALE, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase III pivotal CardiAMP® Cell Therapy Heart Failure Trial (clinicaltrials.gov Identifier: […]